Medical Devices Startups

Glakolens develops a non-invasive biosensor platform embedded in a disposable contact lens to enable continuous 24-hour intraocular pressure monitoring for patients at risk of glaucoma and ocular hypertension. The platform comprises a passive sensor on a soft contact lens and a wearable electronic system that wirelessly collects data during clinic-based monitoring sessions.

1 investor

GlaucoT develops a medical device for the treatment of glaucoma, aiming to provide affordable eye care solutions for glaucoma patients. The company operates in the medical device and ophthalmology technology space.

1 investor

Glaukos develops micro-scale medical devices and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, replacing traditional drop therapies with minimally invasive surgery platforms. Founded in 1998 and publicly traded on the NYSE, the company serves ophthalmology patients globally.

1 investor

Global Cord Blood Corporation is China's leading provider of umbilical cord blood collection, laboratory testing, and hematopoietic stem cell processing and storage services. The company operates as a specialized biobank serving patients and families seeking cord blood banking and stem cell therapies.

1 investor

Globus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.

1 investor

GLX Analytix develops a blood test platform that measures glycocalyx fragments and uses AI/ML to create disease-specific biomarker signatures for diagnosing and monitoring brain diseases including neuropsychiatric, neurodegenerative, and autoimmune conditions. The company targets clinicians and healthcare providers seeking early detection and precision medicine insights for conditions like Parkinson's, multiple sclerosis, schizophrenia, and stroke.

1 investor

Glycologix is a clinical-stage biotechnology company developing locally delivered biopolymers that mimic natural proteoglycans for the protection and repair of soft tissues. Its lead program, GLX-100, targets interstitial cystitis/bladder pain syndrome (IC/BPS), with the technology intended for additional soft tissue indications.

1 investor

Glyconics develops medical diagnostic devices using spectroscopy (light-with-matter technology) to support low-cost medical diagnosis and disease management for patients and healthcare practice.

1 investor

Glycotest develops diagnostic tests for the early detection of liver disease and liver cancer. The company operates in the biomedical diagnostics field within the healthcare industry.

1 investor

Fortell AI manufactures hearing aids that use artificial intelligence to improve speech comprehension in noisy environments, supported by clinical trials and fitted by audiologists.

1 investor

GoodGut develops intellectual property based on the study of individuals' gut microbiota, which plays a role in intestinal immunity and the development of digestive diseases. The company aims to provide diagnostic solutions for digestive conditions to the healthcare system.

1 investor

GRAIL develops a blood-based multi-cancer early detection test called Galleri that uses next-generation sequencing and machine learning to screen for multiple cancer types before symptoms appear. The company serves healthcare providers, insurers, and patients seeking early cancer detection.

1 investor

Grandomics develops third-generation sequencing services and precision genomic medicine solutions for medical diagnostics, plant and animal breeding, and species conservation. The company applies long-read sequencing technology and computational methods to assemble complete genomes and address applications in medicine, crop improvement, and biodiversity protection.

1 investor

GLC Inc. develops custom graphene applications and solutions for global markets. The company licenses graphene technology to partners across various industries to enhance product performance and enable environmental and economic advancement.

1 investor

Graphic Controls (now part of Nissha Medical Technologies) manufactures precision printed and consumable products for industrial monitoring and medical applications, including data recording systems for drilling and exploration. The company serves healthcare, industrial monitoring, and transactional media markets with core manufacturing capabilities in printing, coating, laminating, and molding.

1 investor

Graph AI develops AI-powered patient safety solutions that combine human expertise with machine intelligence to help healthcare professionals make better clinical decisions. The platform emphasizes explainability, governance, and contextual analysis for hospital and healthcare settings.

1 investor

Great Expressions Dental Centers provides administrative and business support services to independently owned and operated dental practices, licensing the brand name to dental offices across multiple states. The company supports dental service providers and their practice operations.

1 investor

Grey Matter Neurosciences develops transcranial focused ultrasound systems combined with drug therapies to treat mood and cognitive disorders in older adults, with an initial focus on non-invasive neuromodulation outside hospital settings.

1 investor

Dental Grip manufactures a precision tool for dentists to safely handle dental prostheses with improved ergonomics and control during clinical procedures.

1 investor

Able Rehab is a digital therapy platform that uses gamified activities to train hand and wrist movements for patients in rehabilitation. It provides objective assessment, personalized training activities, and progress tracking for clinicians managing patient recovery.

1 investor

Grove is developing an orthopaedic system for long bone repair that combines biology with adaptive technology to support natural bone regrowth. The system is aimed at patients and surgeons, seeking to consolidate treatment into a single procedure and provide surgical precision tools.

1 investor

2NA FISH develops a spatial RNA detection platform using nanostructure-enhanced probes for oncology research and pathology workflows. The platform combines brightfield RNA biomarker analysis on standard fluorescence microscopes with AI-powered software for quantification and cell-level readouts.

1 investor

G-Tech Medical develops an electrocardiogram technology for assessing gastrointestinal function. The company serves clinicians and patients in the medical device and healthcare sectors.

1 investor

Guardian Bio develops dendritic cell therapy for solid tumors by generating cDC1 cells from patient stem cells to restore immune function in cancer treatment. The company targets late-stage cancer patients who have dysfunctional antigen presentation.

1 investor